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It has been generally assumed that insulin circulates freely in blood. However it can also
interact with plasma proteins. Insulin receptors are located in the membrane of target cells
and consist of an alpha and beta subunits with a tyrosine kinase cytoplasmic domain. The
ectodomain, called soluble insulin receptor (SIR) has been found elevated in patients with
diabetes mellitus. We explored if insulin binds to SIRs in circulation under physiological
conditions and hypothesize that this SIR may be released by hepatocytes in response to
high insulin concentrations.The presence of SIR in rat and human plasmas and the culture
medium of hepatocytes was explored using Western blot analysis. A purification protocol
was performed to isolated SIR using affinity, gel filtration, and ion exchange chromatogra-
phies. A modified reverse hemolytic plaque assay was used to measure SIR release from
cultured hepatocytes. Incubation with 1 nmol l−1 insulin induces the release of the insulin
receptor ectodomains from normal rat hepatocytes. This effect can be partially prevented
by blocking protease activity. Furthermore, plasma levels of SIR were higher in a model of
metabolic syndrome, where rats are hyperinsulinemic. We also found increased SIR lev-
els in hyperinsulinemic humans. SIR may be an important regulator of the amount of free
insulin in circulation. In hyperinsulinemia, the amount of this soluble receptor increases and
this could lead to higher amounts of insulin bound to this receptor, rather than free insulin,
which is the biologically active form of the hormone. This observation could enlighten the
mechanisms of insulin resistance.
Keywords: diabetes mellitus type 2, hyperinsulinism, insulin resistance, metabolic syndrome, protease
INTRODUCTION
Insulin is the most important hypoglycemic hormone in mam-
mals. It is secreted by pancreatic beta cells in response to glucose
stimulation and enters the portal circulation before inflowing the
general circulation. More than 50% of insulin binds to insulin
receptors (IR) in the liver and is removed from the circulating
blood. The remaining hormone reaches peripheral targets, where
it predominantly promotes anabolic effects in muscle and adipose
tissue.
The IR has been extensively studied for more than 40 years.
It is an acidic protein with an isoelectric point of 4.0 that con-
stitutes a heavily glycosylated disulfide-linked homodimer (1, 2).
Each monomer is formed by an alpha subunit (130 kDa) and a beta
subunit (95 kDa) (3). The entire alpha chain and a short sequence
of the beta chain comprise the ectodomain; beta-subunits have
membrane spanning regions and cytoplasmic tyrosine kinase (TK)
domains (4). The IR belongs to a family of receptors with TK
activity, and it is closely related to the type-1 insulin-like growth
factor receptor (IGF-1R) (5).
Insulin receptors are synthesized as single polypeptides with
a signal sequence that directs the full monomers to insert into
the plasma membrane. During its translocation, internal disulfide
bridges are formed. After a proteolytic cleavage by furin, the pro-
tein is separated into alpha and beta chains, which stays connected
by one disulfide bridge. The monomers further dimerizes by the
formation of two other disulfide bridges between the alpha chains
(6–8). In addition, alpha subunits are heavily glycosylated (9, 10).
The dimeric IR contains both high- and low-affinity binding sites
for insulin.
Insulin receptors are ubiquitous proteins and are distributed
in all tissues at different densities. However, the major targets
of insulin are the liver, which expresses the highest levels of the
receptor, as well as adipose and muscular tissues. The complex
formed between IR and insulin is internalized and transported
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to endosomes, where insulin is degraded by the action of the
insulin-degrading enzyme (IDE). This enzyme is present in all
types of cells, and not only in those with a clear response to insulin.
Down-regulation of the IR was first described in lymphocytes over
40 years ago (11). Recently, the ectodomains of receptors for dif-
ferent hormones, cytokines, and growth factors have been found
to circulate in blood, including a soluble IR ectodomain that was
found to be elevated in the plasma of patients with diabetes (12).
The presence of soluble insulin receptors (SIR) in the blood
raises many questions about its pathophysiology. Firstly, which
tissues are the main contributors to the circulating IR levels? Do
soluble IRs are associated to pathological conditions like metabolic
syndrome (MS)? And last but not least, which are the stimuli that
promote IR release from these tissues?
Several cell lines, including the human hepatoma HepG2 cells,
have been described to release IRs when facing high concen-
trations of insulin (13), a context that resemble the high levels
of circulating insulin in insulin resistance states (14). Interest-
ingly, these cells also release more SIR when stimulated with
high glucose concentrations, indicating that this process can also
be exacerbated in conditions that mimic diabetes mellitus (15).
Furthermore, it has been proposed that insulin promotes the
activity of a proteinase that mediates the release of IRs from
hepatocytes (16). Interestingly, in spontaneous hypertensive rats
(SHR), an increased proteinase activity causes insulin-receptor
cleavage in insulin-sensitive tissues, accounting for a worsening
in glucose homeostasis (17). Indeed, circulating IRs are pos-
itively associated with hyperglycemia, glycoalbumin, and gly-
cated hemoglobin levels in diabetic patients (12), however, the
causal relationships between SIR and insulin resistance are not
well-understood.
On one hand, the reduction in the density of IRs in the plasma
membrane of target tissues may affect glucose handling (17), indi-
cating that insulin resistance is a byproduct of an impaired insulin
signaling. Nevertheless, a more active role may be ascribed for the
remaining circulating receptors, since the injection of exogenous
IRs may cause glucose intolerance in mice (18). Noteworthy, IRs
released from cultured cells preserve the ability to bind insulin
with high affinity (13), a property that is also present, although
with low affinity, in alpha–beta monomers, alpha chains, and the
soluble dimeric ectodomain (5). The latter evidence suggests that
SIR may bind insulin in the plasma and buffer the amount of
insulin available to exert biological effects.
In this study, we explored the possibility that exposure to high
insulin levels induces the release of the IR ectodomain (soluble IR;
SIR) from hepatocytes. We demonstrate that exposure to a high,
physiological concentrations of insulin (1 nmol l−1) induces the
release of SIR into the incubation medium of hepatocytes from
healthy, wild-type male rats. This effect could be partially pre-
vented by inhibiting protease activity. To test if a similar process
could be present in the whole animal, we used a rat model of MS
(19, 20) that presents hyperinsulinemia. We observed that levels
of circulating SIR were increased.
We also explored the presence of SIR in rat plasma and found
that a fraction of the circulating insulin is bound to plasmatic pro-
teins, mostly albumin, and SIR. Furthermore, SIR levels were also
increased in human subjects during hyperinsulinemia episodes,
compared to healthy human adults, in which SIR could also be
detected, albeit at much lower levels.
By extending this scenario, it is possible that SIR increases and
buffers part of the circulating insulin, preventing the development
of hypoglycemia in healthy subjects, in response to high insulin
levels. Moreover, during the hyperinsulinemic episodes in patients
with MS and insulin resistance, despite to the high levels of insulin
detected, a significant proportion of the hormone could not be
biologically available because it is bound to SIR.
MATERIALS AND METHODS
REAGENTS
Dulbecco’s modified Eagle’s medium (DMEM) culture media,
glutamine, gentamicin, and antibiotic–antimycotic solution were
purchased from Life Technologies Corp. (CA, USA). Collagen
type IV, HEPES, dl-dithiothreitol (DTT), pig insulin, sodium
bicarbonate, glucose, sucrose, l-proline, d-(+)-galactose, NaCl,
trizma base, trizma hydrochloride, and glycine were obtained from
Sigma-Aldrich (MO, USA). Acrylamide, N,N′-methylene-bis-
acrylamide, N,N,N ′,N ′-tetramethylethylenediamine (TEMED),
ammonium persulfate, Tween 20, protein standard of molecular
weights, and the protein determination kit, based on the Brad-
ford assay (Cat. 5000-002), were purchased from Bio-Rad (CA,
USA). Amicon YM-3 filters and Immobilion-FL membrane were
obtained from Millipore (MA, USA), fetal bovine serum (FBS)
from Equitech (England), and ECL plus Western blotting detection
systems from General Electric Healthcare (Buckinghamshire, UK).
ANIMALS
All methods used in this study were approved by the Animal
Care Committee of the Instituto de Fisiología Celular, Univer-
sidad Nacional Autónoma de México. Animal care was to the
“International Guiding Principles for Biomedical Research Involv-
ing Animals,” Council for International Organizations of Medical
Sciences, 2010. Wistar rats were obtained from the local animal
facility, maintained in a facility with a 12:12 h light–dark cycle
(06:00-18:00), and allowed free access to standard laboratory rat
diet and tap water.
RAT MODEL OF METABOLIC SYNDROME
We used a model of MS in adult male Wistar rats as previously
reported by our group (19). Briefly, MS was induced in 2-months-
old rats by a hypercaloric diet over 8 weeks, which consisted of a
20% (w/v) sucrose solution as drinking water. The control group
received plain water.
STUDY SUBJECTS
Human blood samples were donated by Dr. Clicerio González
from the Unidad de Investigación en Diabetes, Instituto Nacional
de Salud Pública. Patients were diagnosed with diabetes melli-
tus and had the disease for 1 year or more. As controls, we used
the blood of young healthy Mexican volunteers without a history
of familial diabetes and with a body mass index (BMI) ranging
from 19 to 23. All participants in the Mexico City Diabetes Study
gave an informed consent previously approved by the Institutional
Review Board (IRB) of the Diabetes Center of the Hospital ABC
from Mexico City, which provided ethical and regulatory guidance
for research in the institution.
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The IRB guaranteed the protection of the rights, welfare, and
well-being of human research participants recruited for projects
conducted by investigators of the institutions. To assure the high-
est ethical standards for human research protection, every protocol
adhered to the ethical principles outlined in the Belmont Report
and they were also implemented in accordance to the terms based
on the code of the Mexican federal regulations 45 CFR 46 and
21 CFR 50 and 56. The IRB is registered at the Comisión Fed-
eral para la Protección de Riesgos Sanitarios, COFEPRIS (Federal
Commision for the Protection of Sanitary Risks) and operated in
accordance to the norms and regulations of the Secretaría de Salud
(Health Department) of Mexico, as well as the National Institutes
of Health, USA.
PLASMA SAMPLES
Peripheral blood from study subjects was collected in heparinized
tubes and centrifuged at 302× g at 5°C for 15 min. The super-
natant was recovered and stored at−70°C for further use.
GLUCOSE AND INSULIN DETERMINATION
Glucose and insulin levels were measured using the commercials
kits QuantiChromTM Glucose Assay Kit (Bioassay Systems, Hay-
ward, CA, USA, Cat. DIGL-100) and Ultrasensitive Rat Insulin
ELISA (Mercodia, Uppsala, Sweden; Cat. 10-1173), respectively,
following the manufacturer’s instructions.
PRIMARY CULTURES
Rat hepatocytes were isolated using the method of liver digestion
using portal vein collagenase perfusion as previously described
(21). Hepatocytes were resuspended in sterile phosphate-buffered
saline (PBS), diluted (v/v) with an isosmotic Percoll solution
(45 mL Percoll/4.5 ml of 10× Hanks balanced salt solution and
0.5 ml of 1 mol l−1 Hepes) and centrifuged at 800 rpm for 5 min.
Cell viability ≥85% was estimated by trypan blue exclusion.
Hepatocytes were resuspended in DMEM plus 0.02% (w/v)
bovine serum albumin, 3 mmol l−1 Hepes, 1 mmol l−1 sodium
pyruvate, 6 mmol l−1 sodium bicarbonate, 1 mg/ml galactose,
0.2 mmol l−1 proline, 4 mmol l−1 l-glutamine, 10% (v/v) FBS,
5µg/ml insulin–transferrin–sodium selenite (ITS), streptomycin
(100µg/ml), penicillin (100 units/ml), gentamicin (100 units/ml),
and fungizone (0.25µg/ml). For primary culture, hepatocytes
were plated (2.5× 106) in culture dishes coated with type-1
collagen (1 mg/ml) and allowed to attach over 3 h in attach-
ment medium with 10% FBS under a 5% CO2/95% air atmos-
phere at 37°C (22). Under these conditions of culture, the
hepatocytes were maintained in a quiescent state. After 3 h, the
medium was replaced with 10.6 mmol l−1 glucose, insulin-free
DMEM culture medium (without FBS or albumin), or sup-
plemented with four insulin concentrations (50, 100, 500, or
1000 pmol l−1). Conditioned media from hepatocytes were col-
lected at 100 h post-incubation and then centrifuged (302× g at
5°C for 15 min), concentrated in Amicon centrifugal filters with
a cutoff of 3 kDa at 2150× g and 4°C for 10 min, and stored at
−70° C.
IMMUNOPRECIPITATION
Total protein (2 mg) from plasma were incubated overnight
with 5µl of a monoclonal anti-alpha-IR antibody (200µg/ml,
Antigenix) or anti-insulin antibodies (200µg/ml, cat, sc-9168,
Santa Cruz Biotechnology) and then with 60µl of protein-G
agarose (Upstate, NY, USA) for 2 h and washed with 0.1% (v/v)
TNTE buffer (20 mmol l−1 Tris–HCl, pH 7.5, 120 mmol l−1 NaCl,
0.5% (v/v) Triton-X 100, and 1 mmol l−1 EDTA). Samples were
then centrifuged (9677× g at 4°C for 1 min) and the pellets were
diluted in 50µl sample buffer for electrophoresis.
NATIVE GEL ELECTROPHORESIS
Samples were mixed with Native Charge Buffer (Bio-Rad) at a 1:1
ratio (v/v) and 20–40µg of total protein were loaded on a 5–20%
(w/v) acrylamide–bisacrylamide gradient Tris–glycine gel.
SDS-PAGE ELECTROPHORESIS
Samples were mixed with Laemmli buffer (Bio-Rad) plus
50µmol l−1 DTT at a 1:1 ratio (v/v) and then incubated in
boiling water for 5 min. Samples (20–40µg) were then added
to each well of a 3% (w/v) stacking, 7.5% (w/v) resolving
acrylamide–bisacrylamide Tris–glycine gel with 0.1% (w/v) SDS.
WESTERN BLOT
Proteins were transferred from acrylamide gels to polyvinylidene
fluoride (PVDF) membranes and the membranes were further
stained with Ponceau solution (0.2% v/v) to corroborate the trans-
fer efficiency. PVDF membranes were incubated overnight with
primary antibodies against alpha-IR, albumin, or insulin diluted
in 20 mmol l−1 Tris–HCl, 8 g/l NaCl, and 5% (w/v) non-fat dry
milk. The blots were then incubated using a second antibody con-
jugated to horseradish peroxidase, and finally the membranes were
processed using the ECL plus chemiluminescent kit to visualize the
protein bands. Densitometry was performed on each band signal
using the image analyzer software ImageJ from NIH, USA.
For further information about the antibodies, see the Table 1.
PURIFICATION PROCEDURES
Each run consisted of 1 ml of samples from hepatocyte culture
supernatants that were previously concentrated in Amicon cen-
trifugal filters with a cutoff of 30 kDa at 2150× g and 4°C for
10 min. Then, 50 mg of protein (50% of column capacity) were
resuspended in charge buffer (20 mmol l−1 Tris–HCl, pH 7.4, and
500 mM NaCl), filtered with 0.22µm Millipore membrane filter
Table 1 | Antibody information
Antibody Laboratory Dilution Cat. No.
Insulin (H-6) Santa Cruz
Biotechnology
Polyclonal 1: 1000 Sc-9168
Alpha-IR (N-20) Santa Cruz
Biotechnology
Polyclonal 1: 500 Sc-710
Beta-IR (H-70) Santa Cruz
Biotechnology
Polyclonal 1: 1000 Sc-20739
Beta-IR (C-19) Santa Cruz
Biotechnology
Polyclonal 1: 1000 Sc-711
BSA Millipore Polyclonal 1:1000 07-248
Alpha-IR Antigenix Monoclonal 1:250 MC810888AF
Alpha-IR USBiological Monoclonal 1:250 17661-28A
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(Millipore, Billerica, MA, USA), and injected onto a concanavalin-
A affinity chromatography column. Elution was performed using
20 mmol l−1 Tris–HCl, pH 7.4, and either 600 mmol l−1 glucose
or 300 mmol l−1 beta-methyl-d-mannopyranoside (Sigma).
The retained fractions were pooled and 1 ml aliquots were
subjected to gel filtration for insulin-receptor purification on a
HiLoad 16/20 Superdex 200 column equilibrated and eluted with
50 mmol l−1 Tris–HCl and 500 mmol l−1 NaCl at pH 8 in an Akta
FPLC system (GE Healthcare, USA) at a flow rate of 0.8 ml/min.
Fractions of interest were pooled and desalted by successive wash-
ing steps of three volumes of 50 mmol l−1 Tris–HCl buffer each
followed by centrifugation in Amicon filters with a 3 kDa cutoff.
Then, 1 ml aliquots were charged into a MonoQ HR 5/5 column
pre-equilibrated with 50 mmol l−1 Tris–HCl buffer, and the sam-
ple components were eluted at a flow rate of 0.5 ml/min and a
gradient of 2.5 grades/min of a NaCl solution (1 mol l−1). For each
purification step, the presence of SIR in the collected fractions was
monitored by Western blot.
INSULIN MEASUREMENT
Overnight (12 h) fasted rats were anesthetized and central blood
was collected using a sterile syringe. Blood was placed in
heparinized tubes and centrifuged at 8870× g (4°C for 19 min).
The supernatants were recovered and stored at−20°C before use.
Insulin levels in plasma were measured using an Ultrasensitive
Rat Insulin ELISA kit (Mercodia, Uppsala, Sweden; Cat. 10-1173),
following the manufacturer’s instructions.
PROTEIN-BOUND INSULIN DETERMINATION IN PLASMA
Rat plasmas were centrifuged at 2319× g for 15 min in Amicon
Ultra-4 filters with a cutoff of 30 kDa (Merck Millipore, Billerica,
MA, USA). Insulin concentration in the fraction containing pro-
teins above 30 kDa was determined using the above-mentioned
ELISA kit and adjusting for the concentration factor in each
sample.
REVERSE HEMOLYTIC PLAQUE ASSAY FOR SIR
The reverse hemolytic plaque assay (RHPA) is a useful method to
study secretion in endocrine cells (23, 24). This method was mod-
ified to measure the release of IRs from hepatocyte membranes.
Briefly, after 1 day of culture in attachment medium, the hepa-
tocytes were detached from culture dishes and mixed with equal
volumes of Staphylococcus aureus protein-A-coated sheep erythro-
cytes previously conjugated with alpha-IR (N20) antibodies. The
mixture was introduced to collagen-coated Cunningham cham-
bers to promote cell attachment, and then incubated overnight
in insulin-free medium, medium containing 1 nmol l−1 insulin,
or medium with 1 nmol l−1 insulin and alpha2-macroglobulin
(1.5 mg/ml). We then applied guinea pig complement diluted
(1:40) in Hanks balanced salt solution and supplemented with
200 units/ml penicillin G, 200 mg/ml streptomycin, and 0.1%
(w/v) BSA to Cunningham chambers and incubated them for 1 h.
SIR release was determined by the presence of hemolytic plaques
around the hepatocytes, which resulted from the complement-
mediated lysis of erythrocytes expressing SIR–alpha-IR (N20)
antibody complexes bound to protein A.
To measure SIR release from hepatocytes, the hemolysis plaques
were observed under an inverted light microscope (Nikon, model
TMS-F) and their diameters were measured using a calibration bar.
At least 30 cells were counted per duplicate in each experimental
condition for each culture, and the averages of the immunoplaque
areas were calculated.
DATA ANALYSIS
The statistical analysis was performed using the software Graph-
Pad InStat version 3.00 (GraphPad Software, San Diego, CA,
USA). An unpaired Student’s t -test was used for comparisons
between groups, applying a Welch correction in case of variance
heterogeneity. Correlations between insulin and soluble insulin-
receptor levels were performed using a Pearson test. Graph-
ics were constructed using Origin version 7 (OriginLab Cor-
poration, Northampton, MA, USA). Data are represented as
mean± standard error of the mean (SEM).
RESULTS
INSULIN IS BOUND TO PROTEINS IN THE CIRCULATION
We first explored the formation of protein complexes containing
insulin in plasma samples from control male Wistar rats. We elec-
trophoresed whole plasma samples on native gels and analyzed
protein complexes by Western blot probed with an anti-insulin
antibody (Figure 1A, see Materials and Methods). Strikingly,
insulin-positive bands from normal plasma migrated at a higher
molecular weight than purified, recombinant insulin standards.
FIGURE 1 | Insulin interacts with a soluble receptor in plasma from
control rats. (A) Western blots against insulin after native gel
electrophoresis from an insulin standard (Ins) and a plasma sample from an
adult male Wistar rat (C). Insulin staining for the plasma sample is not
located at the same position as the insulin standard, displaying less
migration in the gel for plasma insulin. (B) Insulin-receptor (alpha-IR)
staining by Western blot after denaturing gel electrophoresis of previously
insulin-immunoprecipitated plasma samples from two control rats (C1
and C2).
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This result could be due to the formation of complexes between
insulin and other circulating proteins. A soluble form of the IR
has been described in diabetic patients (12), and thus we tested if
IR was present in control animals.
We immunoprecipitated insulin from plasma samples using a
specific anti-insulin antibody, and then tested for the presence of
the alpha subunit portion of the IR (SIR) by Western blot. We
observed positive bands ranging in size between 88 kDa and more
than 135 kDa (Figure 1B), suggesting the presence of the extracel-
lular domain of the IR as well as some degradation products. We
also observed another band of >200 kDa in size that could corre-
spond to a precursor of the IR (12). In native gels, we verified that
the bands were detected in the same migrating position for insulin
and SIR (Figure 2).
We measured insulin levels in control rats and animals that
were treated with a hypercaloric diet for 2 months (19). Rats that
were fed with 20% sucrose in drinking water (see Materials and
Methods). After 2 months, the animals that exhibited insulin lev-
els higher than that of control rats (95% Confidence Interval:
2.41–4.84 ng/ml) were included in the MS group for comparison
(Figures 3A,B). For protein-bound insulin determination in rat
plasmas, the samples were fractioned using centrifuge filters with
FIGURE 2 | Western blot against insulin (Ins) and a soluble insulin
receptor (SIR) after native gel electrophoresis from plasma samples of
three adult male Wistar rats. As observed, insulin and SIR bands migrated
at the same position, which reflects the interaction between these
molecules.
a cutoff value of 30 kDa. In both groups, 40% of total insulin was
detected in the fraction with proteins above 30 kDa, which indi-
cates that insulin is bound to plasmatic proteins. Furthermore,
MS rats displayed a twofold increase in the amount of insulin in
the fraction containing proteins above 30 kDa (Figure 3C), which
indicates that insulin binding to high molecular weight proteins
in plasma is exacerbated in MS.
THE LIVER AS A SOURCE OF CIRCULATING SIR
We hypothesized that hepatocytes were strong candidates to be
the tissue that contributes the most to the increased circulating
SIR. After being secreted by pancreatic beta-cells, insulin-enriched
blood from the pancreas enters the liver through portal circu-
lation and a marked percentage of insulin is retained by this
organ. Because hyperinsulinemia increases the cleavage of IRs in
hepatocytes (16), we measured the amount of alpha-IR in the con-
ditioned media of primary cultures of rat hepatocytes incubated
with different insulin concentrations.
After native gel electrophoresis (Figure 4), Western blots from
supernatants showed a similar band to the one observed in
plasma, which increased proportionally with the concentration of
insulin. The increment of SIR levels was insulin dose-dependent
(50 pmol l−1 to 1 nmol l−1), and these concentrations represent a
broad of physiological insulin levels. The presence of SIR detected
FIGURE 3 | MS rats show increased insulin binding to plasmatic
proteins. (A) Western blot from plasma of control rats (lane 1, 2) and MS
rats (3, 4, 5) that were previously separated using different Amicon
centrifugal filters and immunoprecipitated with an insulin receptor
(alpha-IR) in a native gel, stained with an anti-insulin antibody. Observe that
insulin is present in different molecular weight bands, Section “Materials
and Methods.” (B) Rats with metabolic syndrome (MS) show increased
insulin levels when compared to control rats (C). (C) MS rats display higher
insulin levels in the plasmatic fraction containing proteins above 30 kDa,
suggesting higher insulin binding to plasmatic proteins. Bars represent
mean±SEM of control (n=12) and MS rats (n=7), *p<0.05 and
***p< 0.0001.
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FIGURE 4 | Dose-dependent SIR release in the supernatant of cultured
hepatocytes. (A) Representative western blots against SIR in media collected
from cultured hepatocytes incubated with increasing concentrations of
insulin. (B) Comparison of normalized SIR levels determined by densitometry
as the area or (C) the intensity of the bands obtained by Western blot. Bars
represent mean±SEM of control and insulin-treated hepatocytes at 50, 100,
500, and 1000 pmol l−1 (n=3 each),*p<0.05 and **p<0.01 for comparison
with respect to control and †p<0.05 with respect to the 50 pmol l−1 condition.
by Western blot was further corroborated using a three-step purifi-
cation procedure based on the physicochemical properties of SIR.
The IR is a heavily glycosylated protein (25–28) and binds
to Concanavalin-A (Con A) chromatographic columns (1). Gel
filtration using a Superdex G-200 column was performed as pre-
viously reported (2) and high molecular weight fractions were
pooled. Then aliquots were applied to an anion exchange chro-
matography column, according to the acidic isoelectric point of
alpha-IR, which is approximately 4.0 (1, 2). Finally, we detected
IR in the major peak, on the basis of the expected molecular
weight for the SIR monomer. Another band was observed migrat-
ing near 82 kDa and may correspond to an alpha receptor fragment
(Figure 5).
SIR RELEASE IS MEDIATED BY PROTEASES IN PRIMARY CULTURES OF
RAT HEPATOCYTES
It has been previously reported for several cell lines and primary
cultures of different cell lineages that SIR release is mediated
by proteases (17). In order to determine if hyperinsulinemia-
induced release is mediated by a similar mechanism, we per-
formed an RHPA in the presence of the plasma protease inhibitor
alpha2-macroglobulin.
We used a novel variant of a RHPA, which was developed to
unambiguously identify cells that secrete specific proteins (23).
The classic RHPA has been used to detect hormone secretion from
single cells after complement-mediated hemolysis in the presence
of antigen-antibody complexes (see Materials and Methods). In
this modified version, hepatocytes were incubated with protein-
A coated erythrocytes that were pre-incubated with a polyclonal
antibody against the alpha portion of the IR (see Materials and
Methods). Complement was then added, and the hepatocytes
that liberated SIR from their membrane were identified with a
hemolytic halo (Figure 6A).
FIGURE 5 |Three-step purification of SIR from the supernatant of
cultured hepatocytes. Chromatograms from Con-A affinity, gel filtration
Superdex 200, and anionic exchange chromatographies. In each purification
step, the faded fractions were pooled and assessed for α-IR by Western
blot to follow purification. Finally, a representative Western blot of each
collected fraction from the last purification step.
The amount of SIR liberated is directly proportional to the area
of the immunoplaque surrounding the hepatocytes. The size of the
immunoplaques were significantly increased after incubating the
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FIGURE 6 | Insulin-induced SIR cleavage by cultured hepatocytes is
reduced by the protease inhibitor alpha2-macroglobulin (MG).
(A) Microphotographs of representative RHPA assays from control (C),
1 nM insulin-treated hepatocytes, (I), and 1 nmol l−1 insulin-stimulated plus
1.5 mg/ml alpha2-macroglobulin (I+MG). Scale bars: 50µm.
(B) Immunoplaque areas (IPA) as a measure of SIR releasing activity. IPA
was calculated after 24 h of incubation in three experiments in duplicate
except for MG (n=2 in duplicate). Bars represent mean±SEM, **p<0.01
for comparison against control and † †p<0.01 for comparison against
1 nmol l−1 insulin condition. (C) Western blot for SIR of supernatants of
hepatocytes cultured in the same conditions of RHPA for 5 days.
hepatocytes with 1 nmol l−1 insulin, compared to controls without
insulin (Figures 6A,B).
Interestingly, we then included the protease inhibitor alpha2-
macroglobulin in the incubation media with 1 nmol l−1 insulin
and observed that the effect of the insulin was counteracted. This
observation is consistent with a protease-mediated activity of SIR
release. Similar results were observed when proteins from hepa-
tocyte supernatants were resolved on a native gel and analyzed
by Western blot. In this case, the area of the band correspond-
ing to SIR was increased after incubating the hepatocytes with
insulin (1 nmol l−1) and reduced to basal levels when alpha2-
macroglobulin was co-incubated with insulin (Figure 6C). This
experiment demonstrates that hepatocytes are a source of SIR,
probably by preoteolytic cleavage.
PLASMA SIR LEVELS IN RATS AND HUMAN SUBJECTS WITH
HYPERINSULINEMIA
To further characterize the systemic increase of SIR levels in rats
with hyperinsulinemia, plasma samples of control and MS rats
were analyzed by native electrophoresis gels and Western blots
to detect SIR, and albumin. SIR-positive bands in samples from
control and MS rats were further quantified and analyzed by den-
sitometry (Figures 7A,B). The level of SIR in the plasma of MS
rats was twofold higher than in controls, which may be due to
the insulin hypersecretion (Table 2) developed by these animals
(Figure 8).
FIGURE 7 | Plasma SIR is increased in MS rats. (A) Western blots of
native gel electrophoresis from representative plasma samples from
control (C) and metabolic syndrome (MS) rats that show co-migration of
insulin, SIR, and albumin in rat plasma as indicated by the colocalization of
all molecules. The intensity and size of insulin and SIR bands are higher in
MS rats than controls. (B) Comparison of normalized plasma SIR levels
determined by densitometry of Western blot bands. Bars represent
mean±SEM of control (C) and MS rats, *p< 0.05 and **p<0.01.
Table 2 | Plasma insulin and glucose measurements of control and MS
rats.
Rats Insulin (µg/l) Glucose (mg/dl)
Control (n=5) 3.2±0.3 126 : 24
MS (n=9) 13.4±1.2** 186 : 21**
To characterize if our results obtained in rats were simi-
larly observed in humans. We analyzed plasma obtained from
healthy subjects and compared them with hyperglycemic–
hyperinsulinemic patients (Figures 9A,B). Interestingly, we
observed that healthy subjects showed SIR bands, similar to that
observed in the animal model (Figure 9C), moreover in hyperin-
sulinemic subjects there was a clear tendency to an increase in SIR
levels (Figure 9D), although no statistical difference was reached,
perhaps because of the high variability of human parameters and
the relatively small sample here used. However, we found that
insulin levels, although they were not associated with SIR levels in
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FIGURE 8 | Insulin-receptor (alpha-IR) staining by western blot after
denaturing gel electrophoresis of previously
insulin-immunoprecipitated plasma samples from two control rats (C)
and two animals with metabolic syndrome (MS). As observed, the
insulin-receptor positive bands are broader and more intense in the MS rats.
healthy subjects (Figure 9E), they showed a positive correlation in
the group of patients (Figure 9F).
DISCUSSION
In this study we tested the hypothesis that a certain amount of
plasma insulin does not travel freely in circulation, but rather it is
bound to proteins, predominantly produced by the liver. Insulin
binding to proteins would prevent a possible hypoglycemic event
and also protects insulin from fast degradation by IDEs. In states
of insulin resistance, high insulin levels are detected; however,
it is likely that only a small amount of that insulin is free to
interact with the respective targets. The insulin-binding proteins
that we considered in this study were albumin and a SIR. The
observed SIR perfectly coincides with one previously described by
the Insulin-Receptor Group in diabetic patients (12). Neverthe-
less, this study concluded that SIR could be a biological response
to hyperglycemia and we demonstrated that it is a response to high
insulin levels.
A recent study demonstrated that SIR levels are also corre-
lated with the inflammatory protease circulating granzyme B levels
that is increased in type 2 diabetes mellitus (T2DM), and fur-
ther augmented by obesity in patients (29). Furthermore, these
authors found that SIR levels were positively correlated with fasting
plasmatic insulin, suggesting a possible association with a hyper-
insulinemic state. Here, we proposed and demonstrated that high
insulin concentrations promote the liberation of the alpha por-
tion of the IR from hepatocytes, and that a protease inhibitor
FIGURE 9 | Plasma SIR is detected in healthy and diabetic patients.
(A) Fasting plasma glucose levels and (B) insulin, from healthy subjects (H)
and patients (P) that present hyperglycemia and hyperinsulinemia.
(C) Representative Western blots of alpha-IR immunoprecipitated plasma
from healthy subjects and hyperglycemic–hyperinsulinemic patients. Note
that alpha-IR immunoblotting appears in two bands (close to the expected
size for α-IR monomer: 135 kDa, and a fragment around 75 kDa) of a
SDS-PAGE gel. (D) A tendency of higher SIR levels is observed in the
plasma of hyperglycemic–hyperinsulinemic patients. SIR levels were
determined by densitometry of the experiments depicted in (D) and
normalized with respect to the average level of healthy subjects. (E,F)
Show the correlation between the normalized SIR levels and the plasmatic
insulin, which resulted significant for patients. Bars represent mean±SEM
of healthy subjects (N =9) and hyperglycemic–hyperinsulinemic patients
(N =17), *p<0.05.
can prevent this process. The results of in vitro experiments were
in agreement with the once obtained from whole animal sam-
ples, as well as from plasma samples obtained from healthy and
hyperinsulinemic patients.
Hyperinsulinemia and insulin resistance are characteristic signs
of MS, and we previously developed an animal model that reca-
pitulates the disease course seen in humans. We demonstrate
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FIGURE 10 | Mechanism of SIR release from hepatocytes. (A) At
normal insulin levels, SIR is cleaved from hepatocyte membranes by
proteases and passes into the bloodstream, where it retains the
ability to bind insulin and also albumin. SIR acts as a physiological
carrier for insulin. (B) At hyperinsulinemic conditions, SIR is released
and the levels increase in plasma, where it can contribute to insulin
resistance by its high affinity binding of the hormone. (C) Proteinase
inhibitors, such as alpha2-macroglobulin, modulate SIR release by
impeding the cleavage of the insulin receptor within a segment of the
beta-domain.
that SIR is elevated in this model and is also associated with
hyperinsulinemia, compared to controls.
The presence of a plasma SIR is a phenomenon that has been
previously associated with insulin resistance in T2DM in humans
and animal models (12, 18, 30). It has been demonstrated that
IR cleavage is increased in leukocytes from SHR (17), which is
an endogamous strain predisposed to hypertension and insulin
resistance, which are two signs of MS. Most of the previous stud-
ies focused on the reduced ability of target organs to respond
to the circulating insulin levels due to a pathological protease-
mediated excision of the cell surface IRs. However, it is important
to understand its physiological role.
Spontaneous hypertensive rats show enhanced proteolytic
activity in plasma and venules from the mesentery microcircu-
lation compared to normotensive control rats, which is reduced
by protease inhibitors. This activity leads to increased cleavage
of the IR in SHR leukocytes, which can be attenuated by reduc-
ing the matrix metalloproteinase activity with chronic exposure
to doxycycline (17). They also demonstrated that the cleavage of
the IR leads to a 60% reduction of transmembrane transport of
fluorescent glucose (17). Moreover, similar results were obtained
in sand rats (Psammomys obesus) fed with a hypercaloric diet, for
1 month.
Using an insulin solution that was 1000-fold more concen-
trated than the one we used, Sanchez-Casas also detected the
release of a 120 kDa truncated form of IR from hepatocyte plasma
membranes (16). Remarkably, the same study showed a basal
degradation of IRs, which is in agreement with our observation
of low SIR levels, albeit detectable, in the RHPA and Western
blot experiments using hepatocyte supernatants without insulin.
However, these authors were uncertain of the in vivo relevance
of this observation, because they could not detect a significant
increment of SIR levels in plasma. This apparent contradiction
present in most of the studies reporting elevated SIR levels in
T2DM could arise from reliance on the acute hyperinsulinemia
model used by Sanchez-Casas et al., which is different from the
long-term induction of insulin resistance in diabetic or MS mod-
els, as well as the natural, multifactorial development of these
pathologies.
Proteinase inhibitors have the ability to decrease insulin-
dependent receptor release and proteolysis from plasma mem-
branes in IM-9 cells (13) and hepatocytes (16), respectively.
We obtained similar results with one of the tested inhibitors,
alpha2-macroglobulin (16), which reduced the SIR immuno-
plaque areas to basal levels in the insulin-stimulated RHPA, con-
firming a role for proteases in the process of insulin-induced
SIR release from hepatocyte membranes. Hyperinsulinemia also
modulates the activities of hepatic matrix metalloproteinases
and their tissue inhibitors, which could be related to hepatic
fibrosis (31).
It has been shown that intraperitoneal injections of SIR alpha
subunits in mice cause a significant increase in blood-glucose lev-
els as well as glucose intolerance (18). We observed that in an
MS model in rats, SIR levels were also increased. In a previous
study, our group demonstrated that this animal model develops
hyperinsulinemia and insulin resistance after 2 months under a
hypercaloric diet (19). Interestingly, we also observed higher levels
of SIR in hyperinsulinemic patients, compared to healthy sub-
jects. Together, these data suggest that SIR levels may be a marker
of insulin resistance.
A general overview of the novel pathophysiological mecha-
nism leading to insulin resistance, as proposed in the present
work, is depicted in Figure 10. Briefly, hyperinsulinemia increases
the proteolytic activity on surface IRs in hepatocyte membranes.
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This leads to the release of these receptors into the blood-
stream and contributing to insulin resistance through a dual
mechanism, first by decreasing the density of IRs present on
cells and the insulin responsiveness, and second by sequester-
ing the circulating insulin through SIR, which competes with
the membrane-bound receptors for the available insulin in
circulation.
These results open a new field in the study of MS, as we show
that the plasma SIR is an important regulator of free insulin
in blood under both physiological and pathological conditions.
Moreover, we show that hyperinsulinemia is a reflection of high
amounts of insulin bound to proteins at a higher proportion than
free insulin.
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